riximyo
sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastiske midler - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. foreligger kun begrænsede oplysninger om effekt og sikkerhed for patienter, der tidligere er behandlet med monoklonale antistoffer, herunder rituximab eller patienter ildfaste materialer til tidligere rituximab plus kemoterapi. se afsnit 5. 1 for yderligere information. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab har vist sig at reducere hastigheden af progressionen af ledskader, som målt ved hjælp af x-ray, og til at forbedre den fysiske funktion, når det gives i kombination med methotrexat. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).
irbesartan "accord" 150 mg filmovertrukne tabletter
accord healthcare b.v. - irbesartan - filmovertrukne tabletter - 150 mg
lamotrigin "aristo" 25 mg tabletter
aristo pharma gmbh - lamotrigin - tabletter - 25 mg
tetraspan 60 mg/ml infusionsvæske, opløsning
b. braun melsungen - Æblesyre, calciumchloriddihydrat, hydroxyethylstivelse, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning - 60 mg/ml
venofundin 60 mg/ml infusionsvæske
b. braun melsungen - hydroxyethylstivelse, natriumchlorid - infusionsvæske - 60 mg/ml
sumithion na 50 e flydende middel
nordisk alkali - fenitrothion - flydende middel - 500 g/l fenitrothion
electis vanddispergerbart granulat
gowan comércio internacional e serviços, limitada (tidl.: margarita) - zoxamid, mancozeb - vanddispergerbart granulat - 83 g/kg zoxamid ; 667 g/kg mancozeb
herbinass flydende middel
dla agro a.m.b.a. - sprede-klæbemiddel - flydende middel - 1000 g/l sprede-klæbemiddel
predict flydende middel
nordisk alkali - penetreringsolie - flydende middel - 1000 g/l penetreringsolie
yaravita coptrac 500 flydende middel
yara danmark gødning - kobber - flydende middel - 500 g/l kobber